Key stats
- Market cap
- 23.9B
- Open
- —
- Day range
- —
- 52-week range
- $90.39 – $212.75
- Volume
- 5.69K
- Avg volume
- 3.77M
Q3 FY26Miss
Expected$-0.39
Actual$-0.46
INSM
Insmed Incorporated$109.40+$0.09+0.08%Price as of Nov 3, 2026, 9:28 AM ET
Earnings
Q2 FY26
Actual$-0.06
Q1 FY26
Actual$-0.76
Q4 FY25
Actual$-1.53
About
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
- Employees
- 1,664
- Headquarters
- Bridgewater, NJ